#JPM21: Avidity CSO Art Levin runs full speed to the clinic with 'dream' antibody oligonucleotide conjugate therapy

#JPM21: Avidity CSO Art Levin runs full speed to the clinic with 'dream' antibody oligonucleotide conjugate therapy

Source: 
Endpoints
snippet: 

Art Levin is living his “scientist’s dream come true.”

The Avidity Biosciences CSO set out years ago to build a new class of oligonucleotide-based therapies for severe muscle diseases, like myotonic dystrophy (DM1) — the rare, genetic disorder that causes progressive muscle weakness.